SCHEMBL26438880

SCHEMBL26438880

Cc1cccc2nc(C(C)C)ncc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 4/20 0.37
CYP2A6 P11509 3/20 0.37
AURKA O14965 1/20 0.37
AURKB Q96GD4 1/20 0.37
ALDH1A1 P00352 4/20 0.36
PDE3B Q13370 2/20 0.36
PDE3A Q14432 2/20 0.36
PRNP P04156 2/20 0.35
RXFP1 Q9HBX9 2/20 0.35
KMT2A Q03164 2/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
TSHR P16473 2/20 0.34
PDE2A O00408 1/20 0.34
USP2 O75604 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
HPGD P15428 2/20 0.33
HSD17B10 Q99714 2/20 0.33
BACE1 P56817 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26480101 0.83 TLR8 (0.38) CYP1A2CYP2A6ALDH1A1PDE3BPDE3A
SCHEMBL19154658 0.82 LMNA (0.36) CYP1A2AURKAAURKBALDH1A1PRNP
SCHEMBL23978475 0.81 MAPT (0.44) CYP1A2CYP2A6AURKAAURKBPDE3B
SCHEMBL8404379 0.77 CYP1A2 (0.42) CYP1A2CYP2A6ALDH1A1PDE3BPDE3A
SCHEMBL22672620 0.77 HTT (0.41) ALDH1A1KDM4ETSHRHPGDNPC1
SCHEMBL22672522 0.77 PDE7A (0.44) ALDH1A1PRNPRXFP1KMT2AL3MBTL1
SCHEMBL26703046 0.76 LATS1 (0.33)
SCHEMBL24768800 0.75 LMNA (0.57) CYP2A6AURKAAURKBALDH1A1PRNP
SCHEMBL18630330 0.74 CYP1A2 (0.39) CYP1A2CYP2A6ALDH1A1PDE3BPDE3A
SCHEMBL19662807 0.74 ADORA2A (0.49) CYP1A2CYP2A6ALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 US disclosed
US-20230130602-A1 INHIBITORS OF C. DIFFICILE SPORE GERMINATION THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS 2023-04-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 CYP1A2 2939/4885CYP2A6 3947/4885AURKA 3018/4885
US-20230130602-A1 INHIBITORS OF C. DIFFICILE SPORE GERMINATION CDC37, SI, DAD1 CYP1A2 1940/4885CYP2A6 3305/4885AURKA 700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.